相关实验视频

Updated: May 10, 2025

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

前列腺特异性膜抗原正子发射断层扫描用于生物化学复发的新型风险分层

Madeleine J Karpinski¹, Claudia Kesch², Boris A Hadaschik²

¹Department of Nuclear Medicine, DKTK and NCT University Hospital Essen.

Current opinion in urology

|April 24, 2025

概括

准确的风险分层对前列腺癌患者具有生物化学复发 (BCR) 是至关重要的. 前列腺特异性膜抗原正子发射断层扫描 (PSMA-PET) PROMISE (PPP) 诺米图与欧洲泌尿病学协会 (EAU) 的类别相比提供了更好的预测.

科学领域:

在瘤学瘤学.
医疗成像医学成像
泌尿器科泌尿器科泌尿器科泌尿器科

背景情况:

在生化复发 (BCR) 患者中,前列腺癌的攻击性有显著的变化.
准确的风险分层对于有效的患者管理和治疗规划至关重要.
目前欧洲泌尿病学协会 (EAU) 的风险类别可能需要增强,以提高预后准确度.

研究的目的:

审查和比较使用前列腺特异性膜抗原正子发射断层扫描 (PSMA-PET) 的新型风险分层工具与已建立的EAU风险类别.
评估基于PSMA-PET的工具在预测BCR患者的结果方面的性能.

主要方法:

对最近发表的关于前列腺癌风险分层工具的文献综述BCR.
通过前列腺癌分子成像标准化评估 (PROMISE) 指标标准化的PSMA-PET与EAU风险类别的比较.
开发和验证使用PSMA-PET PROMISE (PPP) 度量来预测整体生存的视觉和定量名ograms.

主要成果:

使用PSA翻倍时间和格里森得分的EAU风险分层显示了适度的区分能力,但表明需要改进.
作为预后生物标志物,PSMA-PET已经得到验证.
在PSMA-PET PROMISE (PPP) 诺姆图表中显示出在BCR患者中增强风险分层和整体生存预测的潜力.

结论:

PSMA-PET PROMISE (PPP) 纳米图表解决了改善前列腺癌BCR风险分层的未满足需求.
虽然尚未用于个人患者咨询,但PPP名录可以补充现有的EAU风险类别.
在前列腺癌复发的预后评估中,PSMA-PET成像提供了有前途的进展.

关键词:

欧洲泌尿病学会风险类别风险类别.生物化学复发的发生.前列腺特异性膜抗原正子发射断层扫描前列腺特异性膜抗原正子发射断层扫描 PROMISE nomograms 诺言风险分层的风险分层.

更多相关视频

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...